Nnedu Obinna N, Pankey George A
Infectious Disease Department, Ochsner Clinic Foundation, New Orleans, LA, USA.
Infectious Disease Research, Ochsner Clinic Foundation, New Orleans, LA, USA.
Ther Clin Risk Manag. 2015 Apr 13;11:605-10. doi: 10.2147/TCRM.S57376. eCollection 2015.
Telavancin is a lipoglycopeptide that has activity against Gram-positive aerobic and anaerobic bacteria. It has activity against methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus and non-Van-A strains of vancomycin-resistant enterococci. It has been approved by the US Food and Drug Administration (FDA) for complicated skin and skin structure infections and hospital-acquired pneumonia. There is a need for more clinical studies to determine the role of telavancin in treating bacteremia and prosthetic device infections. In this review, we discuss the published data on the use of telavancin in treating hospital-acquired infections and provide an update on new research.
替考拉宁是一种脂糖肽类药物，对革兰氏阳性需氧菌和厌氧菌具有活性。它对耐甲氧西林金黄色葡萄球菌、万古霉素中介金黄色葡萄球菌以及万古霉素耐药肠球菌的非Van-A菌株具有活性。它已被美国食品药品监督管理局（FDA）批准用于治疗复杂性皮肤及皮肤结构感染和医院获得性肺炎。需要更多的临床研究来确定替考拉宁在治疗菌血症和假体装置感染中的作用。在本综述中，我们讨论了已发表的关于替考拉宁用于治疗医院获得性感染的数据，并提供了新研究的最新情况。
